公开(公告)号：US20230310608A1

公开(公告)日：2023-10-05

申请号：US18003279

申请日：2021-07-01

申请人： TCER ONCOLOGY AB

发明人： Hans GRÖNLUND ,  Rolf KIESSLING ,  Stina WICKSTRÖM

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N5/0784 ,  C12N5/0783

CPC分类号： A61K39/46449 ,  A61K39/4611 ,  A61K39/00119 ,  A61P35/00 ,  C12N5/0639 ,  C12N5/0638 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N2502/1121 ,  C12N2502/1114

摘要： The present invention provides an in vitro method for the manufacture of a dendritic cell (DC) cancer vaccine, said method comprising the steps of: (i) providing a plurality of phagocytosable particles, wherein each phagocytosable particle comprises a core and an antigenic construct tightly associated to the core, wherein the antigenic construct comprises at least one epitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in a subject; (ii) providing a sample of DCs; and (iii) contacting the sample of DCs with the plurality of phagocytosable particles in vitro and under conditions allowing for the phagocytosis of at least one phagocytosable particle by a DC. The present invention also provides a DC cancer vaccine produced by the method of the invention, and the use a DC cancer vaccine of the invention as a medicament and for the ex vivo expansion of anticancer T-cells.